Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial -

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers | Haematological disorders
Summary
The efficacy of ponatinib vs imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia patients could not be assessed due to early trial termination as a result of concerns about vascular adverse events seen in other trials.
UKMi comment
Ponatinib is a BCR-ABL kinase inhibitor. It is currently licensed in the UK for chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) in patients who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Related links: Editorial